Skip to content
Search

Latest Stories

More thought needs to go into women's game: Isa Guha

Former England cricketer Isa Guha on Sunday said disparities still existed between men's and women's cricket but expressed optimism that the Indian women's team will do as good as their their celebrated male counterparts if "equal amount of thought" goes into it.

In a couple of tweets, she pointed out the areas that need to be looked into by the game's stakeholders to "reach equity".


She has also called for the need to have a strong player's association in place for the welfare of the women's game.

"Women are made to feel grateful for progress but there is still so much to be done to reach equity (& that isn't just equal pay). Players associations are a vital part of reaching this. Indian women will dominate the stage when as much thought goes into the their game as the men," Isa tweeted.

"While the men are at a different level there are still base level equities in player welfare. Things like payment/contract times, well-being support networks, domestic structure prof support, maternity provisions, retirement planning are all things can be gained from having a pa (player's association)."

The Indian women cricketers, who made the finals of last year's World T20 in Australia, will receive their share from the $500,000 prize money by the end of this week, a senior BCCI official told PTI on Sunday after it came to light that they are yet to be paid.

A report in the UK's Telegraph newspaper quoted an official from the Federation of International Cricketers Association (FICA) as saying that the BCCI is yet to disburse the runner-up prize money of the global event, which was held in February-March last year.

India were led by Harmanpreet Kaur at the marquee event, where they lost to Australia in the final watched by over 85,000 people at the iconic Melbourne Cricket Ground.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less